This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sudbeck, E. A.
Right arrow Articles by Uckun, F. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sudbeck, E. A.
Right arrow Articles by Uckun, F. M.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 1998, p. 3225-3233, Vol. 42, No. 12
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Structure-Based Design of Novel Dihydroalkoxybenzyloxopyrimidine Derivatives as Potent Nonnucleoside Inhibitors of the Human Immunodeficiency Virus Reverse Transcriptase

Elise A. Sudbeck,1,2,3 Chen Mao,1,3 Rakesh Vig,1,2 T. K. Venkatachalam,1,2 Lisa Tuel-Ahlgren,4 and Fatih M. Uckun1,4,*

Drug Discovery Program,1 Departments of Chemistry,2 Structural Biology,3 and Virology,4 Hughes Institute, St. Paul, Minnesota 55113

Received 7 April 1998/Returned for modification 5 June 1998/Accepted 5 October 1998

Two highly potent dihydroalkoxybenzyloxopyrimidine (DABO) derivatives targeting the nonnucleoside inhibitor (NNI) binding site of human immunodeficiency virus (HIV) reverse transcriptase (RT) have been designed based on the structure of the NNI binding pocket and tested for anti-HIV activity. Our lead DABO derivative, 5-isopropyl-2-[(methylthiomethyl)thio]-6-(benzyl)-pyrimidin-4-(1H)-one, elicited potent inhibitory activity against purified recombinant HIV RT and abrogated HIV replication in peripheral blood mononuclear cells at nanomolar concentrations (50% inhibitory concentration, <1 nM) but showed no detectable cytotoxicity at concentrations as high as 100 µM.


* Corresponding author. Mailing address: Hughes Institute, 2665 Long Lake Road, Suite 330, St. Paul, MN 55113. Phone: (651) 697-9228. Fax: (651) 697-1042. E-mail: fatih_uckun{at}mercury.ih.org.


Antimicrobial Agents and Chemotherapy, December 1998, p. 3225-3233, Vol. 42, No. 12
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:

  • D'Cruz, O. J., Uckun, F. M. (2006). Dawn of non-nucleoside inhibitor-based anti-HIV microbicides. J Antimicrob Chemother 57: 411-423 [Abstract] [Full Text]  
  • D'Cruz, O. J., Uckun, F. M. (2005). Discovery of 2,5-dimethoxy-substituted 5-bromopyridyl thiourea (PHI-236) as a potent broad-spectrum anti-human immunodeficiency virus microbicide. Mol Hum Reprod 11: 767-777 [Abstract] [Full Text]  
  • D'Cruz, O. J., Samuel, P., Uckun, F. M. (2004). PHI-443: A Novel Noncontraceptive Broad-Spectrum Anti-Human Immunodeficiency Virus Microbicide. Biol. Reprod. 71: 2037-2047 [Abstract] [Full Text]  
  • D'Cruz, O. J., Venkatachalam, T. K., Mao, C., Qazi, S., Uckun, F. M. (2002). Structural Requirements for Potent Anti-Human Immunodeficiency Virus (HIV) and Sperm-Immobilizing Activities of Cyclohexenyl Thiourea and Urea Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase. Biol. Reprod. 67: 1959-1974 [Abstract] [Full Text]  
  • Carlson, H. A., McCammon, J. A. (2000). Accommodating Protein Flexibility in Computational Drug Design. Mol. Pharmacol. 57: 213-218 [Full Text]  
  • Uckun, F. M., Bellomy, K., O'Neill, K., Messinger, Y., Johnson, T., Chen, C.-L. (1999). Toxicity, Biological Activity, and Pharmacokinetics of TXU (Anti-CD7)-Pokeweed Antiviral Protein in Chimpanzees and Adult Patients Infected with Human Immunodeficiency Virus. J. Pharmacol. Exp. Ther. 291: 1301-1307 [Abstract] [Full Text]